Stock market today: S&P 500 falls as government shutdown, trade jitters persist
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a $54 million market cap biotech company whose stock has declined 11% in the past week, announced new laboratory findings Tuesday showing that its investigational compound, Telomir-1, reduced the survival of aggressive human pancreatic cancer (PANC-1) cells in laboratory studies. According to InvestingPro data, the company maintains a healthy liquidity position with a current ratio of 2.38, though it remains unprofitable with a loss per share of $0.54 over the last twelve months. The company stated the results were observed in vitro and that Telomir-1 produced a concentration-dependent decrease in both cell viability and mitochondrial activity. According to the company, these effects suggest an influence on cellular energy metabolism and oxidative balance.
Telomir reported that similar results had been previously observed in triple-negative breast cancer and prostate cancer models. In the pancreatic cancer studies, the effect of Telomir-1 was partially reversed by the re-addition of iron, which the company said indicates that iron-dependent processes play a role in the response. The company noted that the incomplete reversal suggests additional metabolic or epigenetic mechanisms may be involved.
The filing stated that Telomir-1 has previously been shown to influence tumor suppressor genes and iron-dependent histone demethylases relevant to pancreatic cancer, including MASPIN (SERPINB5), RASSF1A, STAT1, KDM2B (FBXL10), and KDM6B (JMJD3). These genes and enzymes are associated with DNA methylation, oxidative stress response, and cellular energy regulation, and are often altered in aggressive tumors.
Pancreatic cancer is described in the statement as one of the most difficult malignancies to treat, with a five-year survival rate of about 12 percent. Current treatments, such as FOLFIRINOX and gemcitabine plus nab-paclitaxel, are limited by systemic toxicity and resistance, the company said. Telomir-1 is currently being evaluated preclinically for its ability to modulate epigenetic and metabolic regulators that contribute to cancer cell survival.
Telomir Pharmaceuticals said it plans to expand preclinical research to additional cancer models, including leukemia, and to begin in vivo validation studies as part of its ongoing Investigational New Drug (IND) preparation.
This information is based on a press release statement included in a filing with the U.S. Securities and Exchange Commission.
In other recent news, Telomir Pharmaceuticals has announced several promising developments regarding its lead drug candidate, Telomir-1. The company reported that Telomir-1 has shown significant potential in laboratory studies against triple-negative breast cancer (TNBC), one of the most challenging forms of the disease. The drug demonstrated a dose-dependent reduction in cancer cell survival, with its mechanism involving the regulation of cellular iron and energy balance. In addition, Telomir-1 has also shown efficacy in reactivating key tumor suppressor genes in prostate cancer models. The therapy successfully restored the activity of the MASPIN and RASSF1A genes, which play crucial roles in preventing tumor invasion and metastasis. Furthermore, new in vitro data revealed that Telomir-1 inhibits members of the KDM5 histone demethylase family, which are involved in silencing tumor suppressor genes and activating inflammatory pathways. These findings were detailed in a regulatory filing with the Securities and Exchange Commission. These recent developments highlight Telomir Pharmaceuticals’ ongoing efforts in cancer research and therapy innovation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.